Health policy has become quite challenging and complex, especially in the U.S. Any technology, and ultimately marketed product, must have payment strategies to ensure commercial success. Healthcare delivery is moving from a fee-for-service model to a value-based model. This change in payment structure will inevitably change the type of healthcare products developed and manufactured, and how consumers will use them. Bioscience companies must learn to adapt to the new healthcare delivery paradigm.
MichBio, working with its national bio-industry partners, advocates to improve and/or clarify the healthcare delivery, reimbursement and coverage policies that impact our member pharmaceutical, medical device and diagnostic companies. We actively support rules and strategies that will continue to fuel life-changing product innovation, affordability, quality and access.